1. CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice

3. Program Overview

4. Patient Case 1: De Novo, Metastatic, Non-Aggressive Disease

5. Patient Case 1: Cont’d

6. August 2017: Bone Scan

7. Case Discussion Questions

8. First-Line PALOMA-2 Trial*: PFS Results

9. MONALEESA-2: PFS Update

10. MONARCH 3 Trial Data: PFS

11. Case Discussion Questions

12. MONARCH-3: PFS Bone-Only Disease

13. MONARCH-3: PFS Liver Metastases

14. Case Conclusion

15. Case Conclusion: Cont’d

16. Same Patient Case 1 but Patient Progressed

17. Case Discussion Questions

18. Key Clinical Trials: PFS

19. BOLERO-2 Adverse Events

20. CDK 4 and 6 Inhibitors: Incidence of Neutropenia

21. Cumulative Incidence of AEs >15% During the First 5 Years of Palbociclib Treatment (n = 83)

22. Case Conclusion

23. Case Conclusion: Cont’d

24. PALOMA-3: Postprogression Therapies

25. Patient Case 2: De Novo, Progression on Adjuvant AIs With Liver Metastasis

26. Patient Case 2: Cont’d

27. May 2017: CT Scan

28. Case Discussion Questions

29. MONARCH-3: PFS Liver Metastases

30. CDK4/6 Inhibitors: Consistency of Response

31. MONARCH-2: Incidence of Grade 2/3 Diarrhea

32. Case Conclusion

33. Case Conclusion: Cont’d

34. Patient Case 3: De Novo, Metastatic but Aggressive

35. Patient Case 3: Cont’d

36. Case Discussion Questions

37. Patient Case 3: Continuation

38. Case Conclusion

39. Concluding Remarks

40. Abbreviations

41. Abbreviations (cont)